Previous 10 | Next 10 |
ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately two hours. The Phase 2a part of the study will evaluate the safety, tolerability, subj...
Therapeutic interest in psychedelics has grown as researchers learn more about the potential of these substances to manage the symptoms of different mental-health conditions and improve the well-being of individuals. Now, new research has determined that psychedelic experiences can cause a decr...
2024-06-05 14:37:06 ET Summary Shares of psychedelic medicine developers fall after the FDA panel votes against approving MDMA for PTSD treatment. U.S. private sector job growth falls short of expectations, raising concerns about the labor market. Wells Fargo's Chris Harvey co...
2024-06-05 07:17:36 ET More on ATAI, COMPASS Pathways, etc. ATAI: Enormous Potential Upside But No Clarity Yet Psychedelics Closer To Commercialization; Compass Far And Away The Leader COMPASS Pathways plc (CMPS) Q1 2024 Earnings Call Transcript Biggest stock...
2024-06-04 17:32:04 ET More on psychedelic drug companies ATAI: Enormous Potential Upside But No Clarity Yet Psychedelics Closer To Commercialization; Compass Far And Away The Leader COMPASS Pathways plc (CMPS) Q1 2024 Earnings Call Transcript Psychedelic sto...
A new study looking into the effect of psychedelics on individuals who stutter has determined that the drugs may have some benefits. The documented effects of classic psychedelic drugs such as LSD or psilocybin mushrooms are plenty, with researchers noting that their positive effects can be a r...
2024-05-31 10:43:44 ET More on ATAI, COMPASS Pathways, etc. ATAI: Enormous Potential Upside But No Clarity Yet Psychedelics Closer To Commercialization; Compass Far And Away The Leader COMPASS Pathways plc (CMPS) Q1 2024 Earnings Call Transcript Mind Medicine...
NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s managem...
2024-05-27 09:06:18 ET Summary Shares in key competitors COMPASS Pathways and MindMed have shown signs of recovery but Atai shares have remained unchanged. Major news items, such as FDA approval for MDMA-Assisted therapy and phase III data for COMP-360, are expected to impact the ...
2024-05-23 12:15:00 ET Summary Regulatory risk in the psychedelic industry is decreasing, which is a positive sign for investors. Institutional investors are becoming more willing to invest in leading psychedelic companies through private placements. Analyst Alex Carchidi disc...
News, Short Squeeze, Breakout and More Instantly...
ATAI Life Sciences N.V. Company Name:
ATAI Stock Symbol:
NASDAQ Market:
ATAI Life Sciences N.V. Website:
Alcohol use disorder is a disorder characterized by an inability to stop or control one’s drinking despite adverse health, occupational or social consequences. Conventional treatments include medication, behavioral therapy, and support groups. Even with these treatments, however, many ind...
Psychedelics such as DMT, LSD and psilocybin have demonstrated promise in the treatment of affective symptoms of a range of disorders. These drugs work by inducing an altered state of consciousness , which includes intensified perceptions and emotions, which have been associated with therapeutic...